VRCA
Verrica Pharmaceuticals Inc.
Nasdaq: VRCA · West Chester, PA · Healthcare
$3.53-0.30 (-7.83%)Closed
Market Cap$60.6M
Cash$11.2Mmost recent
Runway4 mo$9.2M Q burn
P/E (TTM)—EPS $-1.68
52-Wk Range$3.28 – $9.10
Avg Volume119.5K3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$3.53-76.5%
Pipeline
Drug candidates sponsored by Verrica Pharmaceuticals · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 3 | Unnamed | Molluscum Contagiosum | Completed | 2018-09-26past | 1 | |
| Phase 3 | Unnamed | Molluscum Contagiosum | Completed | 2018-11-26past | 1 | |
| Phase 3 | Unnamed | Common Warts+3 more | Active, not recruiting | 2026-11 | 1 | |
| Phase 3 | Unnamed | Common Warts+3 more | Recruiting | 2027-05 | 1 | |
| Phase 3 | Unnamed | Common Warts (Verruca Vulgaris)+3 more | Recruiting | 2027-11 | 1 | |
| Phase 2 | Unnamed | Molluscum Contagiosum | Completed | 2018-06-25past | 1 | |
| Phase 2 | Unnamed | Common Wart+11 more | Completed | 2019-05-16past | 1 | |
| Phase 2 | Unnamed | Condylomata Acuminata+7 more | Completed | 2020-05-21past | 1 | |
| Phase 2 | Part 1: VP-315 3 Day Dosing/Week | Basal Cell Carcinoma+4 more | Completed | 2024-04-15past | 1 | |
| Phase 2 | Unnamed | Common Warts+3 more | Not yet recruiting | 2027-04 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for VRCA. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.